Carmell Corporation (CTCX) 시세

CTCX under $2

CTCX under $2

Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity

https://www.businesswire.com/news/home/20230809916251/en/Carmell-Announces-Successful-Closing-of-Merger-with-Axolotl-Biologix-and-Launch-of-a-New-Brand-Identity

CTCX $2.90 #merger complete rsi 22 oversold macd crossover bullish

https://stockcharts.com/h-sc/ui?s=Ctcx

$CTCX - Announces Merger with Axolotl Biologix, a Profitable Regenerative Medicine Company
Up 57% Pre-Market/ Current Price $4.74

Carmell Therapeutics Corp NASDAQ: CTCX*

GoSymbol lookup
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Health Care : Biotechnology | Company profile
Carmell Therapeutics Corporation is a regenerative medicine platform company. The Company is engaged in the development of allogeneic plasma-based bioactive material (PBM) that is designed to boost innate regenerative pathways across a variety of bone and soft tissue indications. The PBM technology is licensed from Carnegie Mellon University and claims the ability to plasticize whole plasma and cross link with genipin, a derivative of the gardenia plant, to provide a controlled degradation profile in vivo. The Company’s lead product, CT-101 Bone Healing Accelerant (BHA), a biologic, is designated by the United States Food and Drug Administration (FDA) as a combination product, containing the Company’s core technology of PBM plus B Tri-Calcium Phosphate (B-TCP) an already approved medical device. The Company has FDA clearance for a Phase II-stage clinical trial designed to study accelerated healing and reduced infections in open tibia (shinbone) fractures with intramedullary rodding.
Carmell Therapeutics Corp NASDAQ: CTCX*

GoSymbol lookup
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Health Care : Biotechnology | Company profile
Carmell Therapeutics Corporation is a regenerative medicine platform company. The Company is engaged in the development of allogeneic plasma-based bioactive material (PBM) that is designed to boost innate regenerative pathways across a variety of bone and soft tissue indications. The PBM technology is licensed from Carnegie Mellon University and claims the ability to plasticize whole plasma and cross link with genipin, a derivative of the gardenia plant, to provide a controlled degradation profile in vivo. The Company’s lead product, CT-101 Bone Healing Accelerant (BHA), a biologic, is designated by the United States Food and Drug Administration (FDA) as a combination product, containing the Company’s core technology of PBM plus B Tri-Calcium Phosphate (B-TCP) an already approved medical device. The Company has FDA clearance for a Phase II-stage clinical trial designed to study accelerated healing and reduced infections in open tibia (shinbone) fractures with intramedullary rodding.